Although it is clear that there is considerable scientific validation towards NHPs to be used in melanoma, future preclinical research should be conducted on screening effective compounds for anti-cancer activity, particularly those with the potential to inhibit NF-κB as it has shown to be a protein involved in the ability for melanoma tumours to proliferate and avoid apoptosis [195]. Here, NFKB1 is linked to melanoma.